To be informed of our future events
and receive our meeting reports.

Join Us

SOIRÉE DU 12 DÉCEMBRE 2018

Conférence & Cocktail AMONETA DIAGNOSTICS / ADEMTECH

Rencontrez le management de deux sociétés innovantes non cotées, en cours de levée de fonds.

AMONETA DIAGNOSTICS S.A.S. (AMONETA) est une société de biotechnologie créée en 2014 et spécialisée dans le développement, la qualification et la commercialisation de biomarqueurs innovants pour les maladies du système nerveux central. AMONETA propose un test pour le diagnostic de la Maladie d’Alzheimer, rapide, non-invasif et fiable, ne nécessitant que quelques gouttes de sang. Les résultats préliminaires montrent une fiabilité du test allant jusqu’à 95% chez l’homme, avec une sensibilité et une spécificité inégalées pour le diagnostic de la maladie d’Alzheimer. Les études cliniques d’AMONETA ont été financées par différents programmes Européens (~8 Mio €).
La levée de fonds en cours sur la plateforme Happy Capital permettra de compléter l’étude clinique finale et le lancement des actions pré-commerciales.

Je m'inscris à l'évènement

SOIRÉE DU 12 DÉCEMBRE 2018

Conférence & Cocktail AMONETA DIAGNOSTICS / ADEMTECH

Rencontrez le management de deux sociétés innovantes non cotées, en cours de levée de fonds.

ADEMTECH est une entreprise française dont le savoir-faire initial est la synthèse de particules magnétiques (breveté) utilisées par des sociétés internationales produisant des tests diagnostics immunologiques. La société développe et commercialise des produits d’une part dans le domaine de la médecine légale et d’autre part dans le domaine des maladies infectieuses en mycologie et parasitologie.

ADEMTECH vient de gagner un marché exclusif avec la police scientifique pour les scènes de crime avec sa gamme de produits d’extraction en biologie moléculaire pour l’identification génétique humaine. ADEMTECH prévoit d’élargir sa gamme de réactifs détectant des agents infectieux destinés aux Hôpitaux (deux sont déjà sur le marché).

La levée de fonds est en cours sur la plateforme Happy Capital.

Je m'inscris à l'événement

Evening of 25th September 2018

Evening of 25th September 2018

PEPTINOV Conference & Cocktail

Meet the management of two innovative start-ups, in the process of raising funds, one specializing in the treatment of chronic inflammatory diseases, the other in cancer treatments:

PEPTINOV is a biotechnology company specializing in the research and development of active immunotherapy for the treatment of chronic inflammatory diseases and in particular osteoarthritis.

Peptinov team:

René AZOULAI, General Director
Hervé DO, CFO and VP Business Development
Jean-François ZAGURY, Founder and Scientific Director

Access to peptinov documents on the crowdfunding website Happy Capital

Access to PEPTINOV documents

SOIRÉE DU 25 SEPTEMBRE 2018

SOIRÉE DU 25 SEPTEMBRE 2018

Conférence & Cocktail PEPTINOV / ONCAMINE

ONCAMINE is a biotechnology company that proposes an intelligent strategy to deprive cancer cells of polyamines, a nutrient essential for their development and multiplication.

J'accède aux documents ONCAMINE

OUR ACTIVITY

Biotech Agora Info

Biotech Agora Info

Accounts of meetings with industry leaders and specialists, interviews, webinars, training modules, on-line access to company data, publications, for:
• Follow innovations in health and life sciences (Biotech, Medtech, Diagnostics, E-health, Big Data, Cleantech, Silver Economy).
• Understand the specificities of the sector
• Understand the positioning and potential of companies

Biotech Agora Cercle

The Biotech Agora private club

Private meetings with leaders and those who make the news in biotechs.

Networking: Leaders, professionals in the healthcare industry, health professionals, researchers, institutions, consultants, fundraisers, business angels, family offices, fund managers, venture capitalists , …

Free Registration

TESTIMONIALS

Biotech Agora successfully resumed the concept of privileged encounters between individual investors passionate about the health sector and leaders of biotechnology companies. Participants are of high quality and aware of the innovations of the different actors. The formula combines conviviality and personalized relationships in an exclusive setting. In summary, a very good springboard to become better acquainted with individual shareholders particularly active in our field.


Marc Karako, VP Finance, Quantum Genomics

I very much appreciated the meeting organized by Biotech Agora and the discussions with the people present at the event.
The format, format and quality of the assistance lent itself very well to presentation and discussion.
This type of meeting has a very positive and pedagogical impact: it helps to maintain a link with investors who are very demanding in order to better understand the achievements and prospects of the company. It was also an opportunity to meet new investors who were not familiar with Cerenis and who were passionate about the subject.
Biotech Agora helps to disseminate objective information. This is important in the current context where a lot of misinformation can easily circulate on networks and forums to maintain a direct link with individual investors.


Jean-Louis Dasseux, PhD, MBA, founder and Ceo of Cerenis Therapeutics

The format of Biotech Agora evenings with a one and a half hour conference followed by a cocktail to continue the discussions in a more informal setting is very appropriate to better understand and deepen the complex subjects.
Too often the topics are overflown and potential shareholders and investors do not always find the answers to their questions.
The presentation made by the company's CEO provides a better understanding of the project's stakes, its strengths in relation to competition, and the various phases of development in which the project fits.
The assistance of investors is enriched by the presence of biotech specialists (analysts, journalists ...) who bring a pedagogical, didactic side and raise the debates. The accessibility and the quality of the exchanges are made possible by the assistance limited to about sixty people.


Alain Fournelle, Chief Financial Office and individual investor passionate abour biotechs

I attended the Biotech Agora Cerenis evening. The presentation was brilliant, with no double talk. No false pretenses. Very good evening. To renew. Do not change anything to the setting of it.
These meetings of leaders in small committees are for me a privileged place of exchange outside the Shareholers’meetings. It also allows me to discover new and beautiful companies to which I would not necessarily have thought and appreciate their potential.
Contacts with other investors also allow to share points of view outside the forums that I do not frequent, and this, for their lack of reliability.


Christian Ladegaillerie, Business angel

Contact us

Follow us